Serine Enrichment in Tumors Promotes Regulatory T Cell Accumulation Through Sphinganine-Mediated Regulation of c-Fos

Scientific Paper Report Discoveries in the field of science often have significant implications for understanding natural phenomena and improving practical applications. Recently, a research paper published in Science Immunology titled “Serine enrichment in tumors promotes regulatory T cell accumulation through sphinganine-mediated regulation of c-...

TH17-Intrinsic IL-1β–STAT5 Axis Drives Steroid Resistance in Autoimmune Neuroinflammation

TH17-Intrinsic IL-1β–STAT5 Axis Drives Steroid Resistance in Autoimmune Neuroinflammation

TH17 Endogenous IL-1β–STAT5 Axis Drives Steroid Resistance in Autoimmune Neuroinflammation Academic Background Steroid resistance is a major challenge in managing various inflammatory diseases, including autoimmune neuroinflammation. T helper 17 (TH17) cells are widely believed to be associated with steroid resistance. However, the specific mechani...

Nucleobase Adducts Bind MR1 and Stimulate MR1-Restricted T Cells

Nucleotide Adduct Binding MR1 and Activation of MR1-Restricted T Cells Academic Background MR1T cells, a recently discovered class of T cells, can recognize antigens presented by MHC class I-related molecule MR1 without microbial infection. These cells exhibit both helper and cytotoxic properties in vitro, but the endogenous antigens they recognize...

LRIG1 Engages Ligand VISTA and Impairs Tumor-Specific CD8+ T Cell Responses

Interaction and Attenuation of Tumor-Specific CD8+ T Cell Responses by LRIG1 and VISTA Academic Background In recent years, the importance of immune checkpoint inhibitors (ICIs) such as Programmed Cell Death Protein 1 (PD-1) and Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) has received increasing attention. These inhibitors significantly improve the s...

TREM2 Deficiency Reprograms Intestinal Macrophages and Microbiota to Enhance Anti–PD-1 Tumor Immunotherapy

TREM2 Deficiency Reprograms Intestinal Macrophages and Microbiota to Enhance Anti–PD-1 Tumor Immunotherapy

TREM2 Deficiency Reprograms Gut Macrophages and Microbiota to Enhance Anti-PD-1 Tumor Immunotherapy Background Immune checkpoint inhibitors (CPIs), such as drugs that block programmed cell death protein-1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein-4 (CTLA-4), have been successfully used to activate anti...